The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases

Publisher： Bentham Science Publishers

E-ISSN： 2212-4055|13|2|121-127

ISSN： 1871-5281

Source： Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets - Inflammation & Allergy), Vol.13, Iss.2, 2014-05, pp. : 121-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progressive Multifocal Leukoencephalopathy and Newer Biological Agents

By Berger Joseph R.  

Drug Safety, Vol. 33, Iss. 11, 2010-11 ,pp. : 969-983

Adis International

Access to resources Recommend Favorite

Treatment options for AIDS patients with progressive multifocal leukoencephalopathy

By Hernández Beatriz   Dronda Fernando   Moreno Santiago  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 403-416

Informa Healthcare

Access to resources Recommend Favorite

Natalizumab: Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: case report

By  

Reactions Weekly, Vol. 1, Iss. 1406, 2012-01 ,pp. : 28-29

Adis International

Access to resources Recommend Favorite

Natalizumab: Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome: case report

By  

Reactions Weekly, Vol. 1, Iss. 1384, 2012-01 ,pp. : 42-43

Adis International

Access to resources Recommend Favorite

Natalizumab: Progressive multifocal leukoencephalopathy and fatal immune reconstitution inflammatory syndrome: 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1416, 2012-01 ,pp. : 33-33

Adis International

Access to resources Recommend Favorite